This report was first published by Endpoints News. To see the original version, click here
GSK no longer plans to collaborate on a closely-watched RNA editing program from Wave Life Sciences, whose fate could influence the prospects of the emerging field.
Wave announced Monday that GSK returned rights to its RNA editing treatment for AATD, a rare condition that can damage the lungs and liver. Wave’s experimental treatment is among the furthest along RNA-editing programs in clinical trials.
您已阅读20%（492字），剩余80%（1959字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。